Ranbaxy shuts two sites

Share this article:

Ranbaxy has clamped down on shipments from two of its plants. Reuters reports that the drugmaker, which is controlled by Daiichi Sankyo, has voluntarily halted shipments from its Toansa and Dewas plants. The FDA banned Toansa shipments last month, and Dewas-produced products in 2013.

Reuters says Ranbaxy has not discussed the financial implications, but says the closures mean that the company may need to raise generic drug prices because it will have to outsource some of its production.

“This voluntary decision was taken as a precautionary measure...to better allow the company to assess and review the process and controls,” the generics company said in a statement. Reuters notes that Indian regulators inspected the Toansa site two weeks ago, but have not yet released the findings.

Tuesday's move comes soon after FDA Commissioner Margaret Hamburg's visit to the country. The commissioner said the 10-day trip was important, and that India needs to participate and take a role in international discussions about drug quality.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters